Specialty Pharmacy

As the industry focuses more on value-based care, predictive modeling allows pharmacies to shift their services from a one-size-fits-all approach to a personalized, high-touch strategy.

Top news of the day from across the health care landscape.

New technique addresses the tendency of most CAR-T therapies to provoke immune responses against healthy tissues in patients.

Several viable models continue to emerge for addressing the unique challenges of payment and financing for innovative, durable, curative gene and cell therapies.

Not only is cancer control a matter of public health, but its value should be viewed as an investment with considerable human and economic returns, according to a newly released report from the World Health Organization (WHO). Furthermore, although disparities between cancer care in lower- and higher-income countries may seem overwhelming, the report emphasized that they are entirely solvable with effective national cancer control plans.

Top news of the day from across the health care landscape.

The mechanism behind HIV resistance affects the ability of integrase strand transfer inhibitors to bind and block the HIV enzyme integrase.

Health systems, including inpatient and non-acute environments, will have a nearly 4% price increase for pharmaceutical purchases in the coming year, according to the report.

Top news of the day from across the health care landscape.

Canakinumab, a fully human monoclonal antibody, targets interleukin-1β, has anti-inflammatory effects, and is FDA-approved for rheumatologic disorders. Interleukein-1β is a cytokine that drives the interleukin(IL)-6 signaling pathway in inflammatory response.

Top news of the day from across the health care landscape.

As technology gains more of a foothold within the health care landscape, pharmacy professionals have an opportunity to harness the power of data and automatization.

Top news of the week from Specialty Pharmacy Times.

The decision is based on early academic clinical trial data that demonstrated ex-vivo autologous HSC gene therapy being an ideal approach for the treatment of X-CGD, a rare, life-threatening, inherited disease of the immune system.

Although there are no approved therapies for FSHD, researchers at Fulcrum Therapeutics discovered that inhibition of p38α/β reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD.

Some REMS programs may only require a medication guide to be distributed with each dispense that highlight safety information, such as relevant adverse events and risks associated with taking the product.

DSG3-CAART is designed to target the cause of mucosal pemphigus vulgaris while sparing normal B cell populations that provide immunity from infection.

Top news of the day from across the health care landscape.

Electronic health records and the data created are being used on multiple levels and continue to be a driving force for improving care and lowering health care costs.

Top news of the day from across the health care landscape.

A combination therapy may counter the resistance to human epidermal growth factor receptor 2 inhibitor neratinib in patients with breast, ovarian, lung, or other cancers.

Research may help to develop usable hematopoietic stem cells that could regrow a patient with leukemia’s blood system after chemotherapy and irradiation.

Specialty pharmacists are well positioned to manage the opioid epidemic because they are in regular contact with their patients who trust them.

Dupilumab has been granted priority review as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.

Top news of the day from across the health care landscape.

Robust data show the efficacy of tenofovir disoproxil fumarate with emtricitabine for pre-exposure prophylaxis in all priority populations with a risk for HIV.

The study was the first to explore sociodemographic disparities in young adult patients with colorectal cancer.

Top news of the day from across the health care landscape.

Report demonstrates an increase in generic and new drug approvals, Orphan Drug designations, and an increase in the use of expediated approval programs.

Two large studies demonstrating patient-reported outcomes showed that quality of life was maintained longer with newer drug combinations compared with standard of care for the treatment of patients with a specific type of colorectal cancer (CRC) and unresectable hepatocellular carcinoma (HCC). The results were presented at the 2020 Gastrointestinal Cancers Symposium in San Francisco, California, from January 23-25.